Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)

被引：4
|
作者：
Trigo, J. [1 ]
Cho, B. C. [2 ]
Park, K. [3 ]
Girard, N. [4 ]
Viteri, S. [5 ]
Garrido, P. [6 ]
Krebs, M. G. [7 ,8 ]
Thayu, M. [9 ]
Knoblauch, R. E. [9 ]
Xie, J. [9 ]
Bauml, J. M. [9 ]
Schnepp, R. W. [9 ]
Londhe, A. [9 ]
Mahadevia, P. [9 ]
Leighl, N. [10 ]
机构：
[1] Hosp Univ Virgen Victoria & Reg, IBIMA, Malaga, Spain
[2] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[3] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[4] Inst Curie, Thorax Inst, Paris, France
[5] UOMI Canc Ctr, Clin Mi Tres Torres, Barcelona, Spain
[6] Hosp Univ Ramon & Cajal, IRYCIS, Madrid, Spain
[7] Univ Manchester, Fac Biol Med & Hlth, Div Canc Sci, Manchester, Lancs, England
[8] Christie NHS Fdn Trust, Manchester Acad, Hlth Sci Ctr, Manchester, Lancs, England
[9] Janssen R&D, Spring House, PA USA
[10] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
20P
引用
收藏
页码：S38 / S39
页数：2
相关论文
共 50 条
  • [21] Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non-Small Cell Lung Cancer
    Haddish-Berhane, Nahor
    Su, Yaming
    Russu, Alberto
    Thayu, Meena
    Knoblauch, Roland E.
    Mehta, Jaydeep
    Xie, John
    Gibbs, Eric
    Sun, Yu-Nien
    Zhou, Honghui
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 (03) : 468 - 477
  • [22] An adjusted comparison of amivantamab phase II data versus real-world clinical management in France of EGFR exon 20 insertion-mutated (ex20ins) advanced NSCLC patients
    Chouaid, C.
    Perualila, N.
    Debieuvre, D.
    Quantin, X.
    Diels, J.
    Rahhali, N.
    Toueg, R.
    Simon, G.
    Bosquet, L.
    Filleron, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1064 - S1065
  • [23] Pembrolizumab and chemotherapy in non-small cell lung cancer with EGFR ex20ins mutation: A case report
    Zhang, Meng
    Nie, Ligong
    Cheng, Yuan
    THORACIC CANCER, 2021, 12 (20) : 2803 - 2806
  • [24] Understanding the diagnostic and treatment landscape in EGFRm advanced non-small cell lung cancer (aNSCLC) patients with exon 20 insertion mutations (Ex20ins)
    Bailey, H.
    Nasirova, F.
    Sermon, J.
    Rodrigues, B.
    Khela, K.
    Hall, J.
    Last, M. J.
    Penton, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S975 - S976
  • [25] Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer
    Xie, Yuhao
    Lu, Qisi
    Wang, Jing-Quan
    Bo, Letao
    Ashby, Charles R., Jr.
    Chen, Zhe-Sheng
    DRUGS OF TODAY, 2022, 58 (08) : 389 - 398
  • [26] REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations
    Yu, Helena Alexandra
    Besse, Benjamin
    Nishio, Makoto
    Cheng, Ying
    Wei, Li
    Wacheck, Volker
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] EGFR exon 20 insertion mutations in non-small cell lung cancer
    Wang, Fenfang
    Li, Chenghui
    Wu, Qihuan
    Lu, Hongyang
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2982 - 2991
  • [28] Comprehensive analysis of next generation sequencing and ARMS-PCR for detecting EGFR exon 20 insertion (ex20ins) mutations in Chinese non-small cell lung cancer patients
    Xu, Yuyin
    Jia, Liqing
    Jiang, Ling
    Wang, Haochen
    Jiang, Lin
    Feng, Xu
    Wei, Ran
    Yao, Qianlan
    Ren, Min
    Xue, Tian
    Li, Yuan
    Zhu, Xiaoli
    Zhou, Xiaoyan
    Bai, Qianming
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (05) : 986 - 997
  • [29] EFFECTIVENESS OF TREATMENTS IN ADVANCED NON-SMALL CELL LUNG CANCER WITH EXON 20 INSERTION EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS
    Wu, Jenn-Yu
    Shih, Jin-Yuan
    Yu, Chong-Jen
    RESPIROLOGY, 2018, 23 : 168 - 168
  • [30] REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
    Nishio, Makoto
    Yu, Helena Alexandra
    Besse, Benjamin
    Cheng, Ying
    Tan, Daniel Shao-Weng
    Wei, Li
    Wacheck, Volker
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : TPS219 - TPS219
12345